RP-6306 (oral PKMYT1 inhibitor)

DRUG2 trials

Sponsors

Debiopharm International SA

Conditions

Adult Solid TumorAdvanced Solid Tumor

Phase 1

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

TerminatedNCT05147350

Debiopharm International SAAdvanced Solid Tumor

Start: 2022-08-09End: 2025-02-12Updated: 2025-12-05

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

TerminatedNCT05147272

Debiopharm International SAAdult Solid Tumor

Start: 2021-12-16End: 2024-08-28Updated: 2025-12-05

Related Papers

Abstract IA010: Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic

Molecular Cancer Therapeutics2024-06-10

Abstract A017: Characterizing intratumoral heterogeneity of <i>CCNE1</i> amplification in ovarian cancer using digital pathology

Molecular Cancer Therapeutics2024-06-10

Abstract A023: Preclinical development of PKMYT1 and WEE1 inhibitor combinations

Molecular Cancer Therapeutics2023-12-013 citations

Abstract 2132: Tumor heterogeneity of <i>CCNE1</i> copy number assessed by fluorescence <i>in situ</i> hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression

Cancer Research2023-04-04